{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lantus", "query": { "intervention": "Lantus" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 306, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lantus&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T09:23:41.004Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02197520", "title": "A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin Peglispro", "type": "DRUG" }, { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "Insulin Lispro", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2014-07", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2018-11-01", "last_synced_at": "2026-09-03T09:23:41.004Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02197520" }, { "nct_id": "NCT04605991", "title": "A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "LY900014", "type": "DRUG" }, { "name": "Insulin Glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 187, "start_date": "2020-11-04", "completion_date": "2022-02-04", "has_results": true, "last_update_posted_date": "2023-03-03", "last_synced_at": "2026-09-03T09:23:41.004Z", "location_count": 30, "location_summary": "Concord, California • Escondido, California • Fresno, California + 25 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04605991" }, { "nct_id": "NCT00127634", "title": "Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Human Insulin Inhalation Powder", "type": "DRUG" }, { "name": "Injectable Insulin", "type": "DRUG" }, { "name": "Insulin Glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 385, "start_date": "2005-07", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2018-03-09", "last_synced_at": "2026-09-03T09:23:41.004Z", "location_count": 35, "location_summary": "Sacramento, California • Walnut Creek, California • Aurora, Colorado + 32 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00127634" }, { "nct_id": "NCT01476475", "title": "Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine /lixisenatide Fixed Ratio Combination", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Metformin (Background drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 323, "start_date": "2011-11", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-09-03T09:23:41.004Z", "location_count": 14, "location_summary": "Little Rock, Arkansas • Paramount, California • Larenceville, Georgia + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Paramount", "state": "California" }, { "city": "Larenceville", "state": "Georgia" }, { "city": "Roswell", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476475" }, { "nct_id": "NCT02930044", "title": "Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetic Ketoacidosis" ], "interventions": [ { "name": "Early administration of subcutaneous insulin glargine dose", "type": "OTHER" }, { "name": "IV insulin infusion", "type": "OTHER" }, { "name": "IV fluid repletion", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 18, "start_date": "2016-10", "completion_date": "2021-11-01", "has_results": false, "last_update_posted_date": "2022-04-01", "last_synced_at": "2026-09-03T09:23:41.004Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02930044" }, { "nct_id": "NCT01499095", "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lantus (Insulin glargine)", "type": "DRUG" }, { "name": "HOE901-U300 (new formulation of insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 811, "start_date": "2011-12", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2022-03-23", "last_synced_at": "2026-09-03T09:23:41.004Z", "location_count": 110, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01499095" }, { "nct_id": "NCT00975286", "title": "24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Thiazolidinedione (TZD)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 446, "start_date": "2009-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-09-03T09:23:41.004Z", "location_count": 23, "location_summary": "Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Mountain Home", "state": "Arkansas" }, { "city": "Concord", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00975286" }, { "nct_id": "NCT00135941", "title": "Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "insulin glargine", "type": "DRUG" }, { "name": "insulin glulisine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 582, "start_date": "2005-08", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2009-06-04", "last_synced_at": "2026-09-03T09:23:41.004Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00135941" }, { "nct_id": "NCT02738151", "title": "Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin glargine, 300U/mL", "type": "DRUG" }, { "name": "Insulin degludec, 100 U/mL", "type": "DRUG" }, { "name": "Non-insulin anti-diabetic treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 929, "start_date": "2016-05-19", "completion_date": "2017-08-15", "has_results": true, "last_update_posted_date": "2018-09-14", "last_synced_at": "2026-09-03T09:23:41.004Z", "location_count": 74, "location_summary": "Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Chino", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02738151" }, { "nct_id": "NCT00283751", "title": "Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin detemir", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 583, "start_date": "2003-03", "completion_date": "2004-11", "has_results": false, "last_update_posted_date": "2017-01-27", "last_synced_at": "2026-09-03T09:23:41.004Z", "location_count": 21, "location_summary": "Greenbrae, California • La Mesa, California • West Palm Beach, Florida + 16 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00283751" } ] }